This is a news story, published by Guardian, that relates primarily to Gilead Sciences news.
For more latin america economy news, you can click here:
more latin america economy newsFor more news from Guardian, you can click here:
more news from GuardianOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like this article about latin america economy, you might also like this article about
HIV prevention drug lenacapavir. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest manufacturer Gilead Sciences news, high HIV rates news, news about latin america economy, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
generic lenacapavirGuardian
•
79% Informative
Gilead Sciences has signed agreements with six manufacturers to make and sell generic lenacapavir in 120 “high-incidence, resource-limited” countries.
But campaigners said the deal “abandons’ many countries with a high HIV burden, particularly in Latin America , and urged transparency over exact pricing.
The drug, given as a twice-yearly injection, has shown strong results for HIV prevention.
VR Score
81
Informative language
83
Neutral language
14
Article tone
formal
Language
English
Language complexity
63
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
2
Source diversity
2
Affiliate links
no affiliate links